Active, not recruitingNo phase
US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
Key facts
- Who runs it
- CereVasc Inc
- Where
- Boston, Buffalo, Jacksonville, Kansas City, Lexington, New Haven, New York, Providence, Richmond, Rochester, and The Bronx, United StatesSee the 11 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 50 people, planned
- Started
- 20 Apr 2022
- Expected to end
- 30 Jun 2030
- Type of study
- Interventional
- Treatments tested
- eShunt Implant
- Record updated
- 19 June 2025
Who can take part
- Age
- 65 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Patients 65-85 years old for whom traditional CSF shunt placement is indicated based upon a diagnostic normal pressure hydrocephalus (NPH) evaluation
- Patient or legally authorized representative is able and willing to provide written informed consent
- History or evidence of gait impairment duration ≥6 months
- Clinical presentation consistent with NPH including 2 or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with:; Brain MRI signs of ventricular enlargement disproportionate to cerebral atrophy (Evans' Index >0.3) and the absence of severe hippocampal atrophy; Pre-procedure spinal tap test or lumbar drain with subsequent gait disturbance improvement (Timed Up and Go Test) of at least 20%; CSF opening pressure ≥8 cmH2O; Baseline cognitive evaluation assessed by Montreal Cognitive Assessment (MoCA) test score ≥12
- Pre-procedure MRI confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by subject screening committee (SSC)
- Pre-procedure CT confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC
Who cannot take part
- Prior or existing shunts, endoscopic third ventriculostomy, or any previous surgical intervention for hydrocephalus
- Currently participating in another investigational drug or device trial that could conflict with study data collection or follow-up
- Active systemic infection or infection detected in CSF
- Hypersensitivity or contraindication to heparin or radiographic contrast agents which cannot be adequately pre-medicated, desensitized or where no alternative is available
- Atrial septal defect or patent foramen ovale identified on cardiac echocardiogram
- History of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency
- Stroke or transient ischemic attack within 180 days of eShunt Procedure
- Presence of a deep vein thrombosis superior to the popliteal vein
- Other medical illnesses that may cause the patient to be non-compliant with the protocol or confound data interpretation
- International Normalized Ratio (INR) or Partial Thromboplastin Time (PTT) results outside of normal range (INR 0.8-1.4; PTT 25-35 seconds)
- Unable to walk 10 meters (33 feet) with or without an assistive device
- Signs or symptoms of obstructive hydrocephalus
- Occlusion or stenosis of the internal jugular vein
- Venous distension in the neck on physical exam
- Presence of a posterior fossa tumor or mass
- Life expectancy < 1 year
- Unwilling or unable to comply with follow-up requirements
Where in United States
- Beth Israel Deaconess Medical CenterBoston, United StatesNo longer taking part
- University at BuffaloBuffalo, United StatesNo longer taking part
- Baptist HealthJacksonville, United StatesNo longer taking part
- University of Kansas Medical CenterKansas City, United StatesNo longer taking part
- University of Kentucky Research FoundationLexington, United StatesNo longer taking part
- Yale UniversityNew Haven, United StatesNo longer taking part
- NYU Langone HealthNew York, United StatesNo longer taking part
- Rhode Island HospitalProvidence, United StatesNo longer taking part
- Virginia Commonwealth UniversityRichmond, United StatesNo longer taking part
- University of Rochester Medical CenterRochester, United StatesNo longer taking part
- Montefiore Medical CenterThe Bronx, United StatesNo longer taking part
About the trial
What the trial wants to find out
The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
The group in the trial
- Treatment ArmTreatment being tested
The Treatment Arm receives the eShunt Implant.
Treatment: eShunt Implant
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- US Pilot Study to Evaluate the Safety and Effectiveness of the CereVasc® eShunt® System in the Treatment of Normal Pressure Hydrocephalus
- Publications
- Safety of endovascular shunting for normal pressure hydrocephalus from a prospective, multicenter, single-arm study.Journal of neurointerventional surgery, 2026
- Record updated
- 19 June 2025